Kanavos, Panos 
ORCID: 0000-0001-9518-3089, Alcaraz, OA, Chávez, Danitza, Colaci, C, Haig, Madeleine, Argento, F, Main, Caitlin, Alfie, Verónica, Mills, Mackenzie, Pichon-Riviere, DA and Augustovski, F
(2023)
HTA187 Advancing a collaborative value assessment framework for Next-Generation Sequencing/ Comprehensive Genomic Profiling in Europe: building on and enhancing an existing framework - a multi-stakeholder web-Delphi approach.
Value in Health, 26 (12).
S355 - S355.
ISSN 1098-3015
Abstract
Objectives To develop a validated collaborative value assessment framework for Next Generation Sequencing (NGS) / Comprehensive Genomic Profiling (CGP) to a European context. Methods A four round web-Delphi process was used to identify, score, and generate consensus on value indicators for NGS/CGP technologies. An initial list of 18 broad value domains and 49 individual value indicators were identified through a Systematic Literature Review and adaptation of a previously published LATAM-focused value framework (Augustovski et al., Value Health, 2021). Participants are asked to provide feedback on the inclusiveness, appropriateness, and clarity of value indicator definitions (Round 1), and rank value indicators on a Likert scale (1-5) to assess their perceived importance (Rounds 2-4). A thematic analysis was conducted between the first two rounds. Value domains/indicators that achieve over 70% consensus (rate as important or very important) will be included in the final framework. Results A total of 43 stakeholders from various European countries, including patient advocacy, decision-makers, HTA environment, regulators, academia, industry, and physicians, participated in the Delphi. Following feedback from Round 1 [n=39], the initial framework was refined, resulting in 8 domains and 29 indicators. Preliminary results from Round 2 [n=36] indicate that all domains and seventeen indicators have achieved consensus. The highest consensus indicators include informed consent and transparent communication [94%], clinical efficacy [92%], test performance [92%], consequences of wrong diagnosis [91%], quality of scientific evidence [86%], and unmet need [84%]. At least one indicator per domain has achieved consensus in Round 2. The final adapted framework will be made available after the completion of the fourth round. Conclusions The value of NGS/CGP technologies is multidimensional. While clinical efficacy and test performance are crucial, other value constructs should also be considered for reimbursement and coverage considerations related to NGS/CGP technologies in oncology.
| Item Type: | Article |
|---|---|
| Official URL: | https://www.valueinhealthjournal.com/ |
| Divisions: | Health Policy LSE Health |
| Subjects: | R Medicine > RA Public aspects of medicine |
| Date Deposited: | 08 Jul 2024 16:30 |
| Last Modified: | 01 Nov 2024 05:47 |
| URI: | http://eprints.lse.ac.uk/id/eprint/124136 |
Actions (login required)
 |
View Item |
